Recent Finacing
Recent Raise
Osmol Therapeutics is a New Haven biopharma developing OSM-0205, an NCS1-targeting therapy licensed from Yale to prevent chemotherapy-induced peripheral neuropathy, advancing IND, Phase 1 and Phase 2 studies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Osmol Therapeutics.
